S-1MEF 1 tm215210d6_s1mef.htm S-1MEF

As filed with the U.S. Securities and Exchange Commission on February 25, 2021.

 

Registration No. 333-        

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

 

FORM S-1

 

REGISTRATION STATEMENT

UNDER THE SECURITIES ACT OF 1933

 

 

 

Ibere Pharmaceuticals

(Exact name of registrant as specified in its charter)

 

Cayman Islands   6770   98-1564986
(State or other jurisdiction of
incorporation or organization)
  (Primary Standard Industrial
Classification Code Number)
  (I.R.S. Employer
Identification Number)

 

 

 

2005 Market Street, Suite 2030

Philadelphia, PA 19103

(267) 765-3222

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

 

 

 

Osagie Imasogie

Chief Executive Officer

c/o Ibere Pharmaceuticals

2005 Market Street, Suite 2030

Philadelphia, PA 19103

(267) 765-3222

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

 

 

 

Copies to:

 

Carmelo M. Gordian, Esq.
Michelle D. Kwan, Esq.
Cassandra V. Cuellar, Esq.
Shearman & Sterling LLP
300 West 6th Street, Suite 2250
Austin, Texas 78701
(512) 647-1900

Douglas S. Ellenoff, Esq.
Stuart Neuhauser, Esq.

Richard Baumann, Esq.

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas
New York, New York 10105
(212) 370-1300

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ¨

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x 333-252863

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer x Smaller reporting company x
      Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

 

 

 

CALCULATION OF REGISTRATION FEE

 

Title of Each Class of Security Being Registered  Amount
Being Registered(2)
   Proposed
Maximum
Offering Price per
Security(1)
   Proposed Maximum
Aggregate Offering
Price(1)
   Amount of
Registration Fee
 
Units, each consisting of one Class A ordinary share, $0.0001 par value per share, and one-half of one redeemable warrant   2,300,000   $10.00   $23,000,000   $2,509.30 
Class A ordinary shares included as part of the units(3)   2,300,000            (4)
Redeemable warrants included as part of the units(3)   1,150,000            (4)
Total            $23,000,000   $2,509.30(5)

 

(1)Estimated solely for the purpose of calculating the registration fee.

(2)Represents only the additional number of securities being registered. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-252863).

(3)Pursuant to Rule 416 under the Securities Act, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from share splits, share dividends or similar transactions.

(4)No fee pursuant to Rule 457(g) under the Securities Act.

(5)The Registrant previously registered securities having a proposed maximum aggregate offering price of $115,000,000 on its Registration Statement on Form S-1, as amended (File No. 333-252863), which was declared effective by the Securities and Exchange Commission on February 25, 2021. In accordance with Rule 462(b) under the Securities Act, an additional number of securities having a proposed maximum offering price of $23,000,000 is hereby registered, which includes securities issuable upon the exercise of the underwriters’ over-allotment option.

 

The Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Registration Statement on Form S-1 is being filed with respect to the registration of 2,300,000 additional units of Ibere Pharmaceuticals, a Cayman Islands exempted company (the “Registrant”), each consisting of one Class A ordinary share and one-half of one redeemable warrant, pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction V to Form S-1. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment, and only whole warrants are exercisable. This Registration Statement relates to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-252863) (the “Prior Registration Statement”), initially filed by the Registrant on February 9, 2021 and declared effective by the Securities and Exchange Commission (the “Commission”) on February 25, 2021. The required opinions of counsel and related consents and accountant’s consent are attached hereto and filed herewith. Pursuant to Rule 462(b), the contents of the Prior Registration Statement, including the exhibits thereto, are incorporated by reference into this Registration Statement.

 

CERTIFICATION

 

The Registrant hereby certifies to the Commission that (1) it has instructed its bank to pay the filing fee set forth on the cover page of this Registration Statement by a wire transfer of such amount to the Commission’s account at U.S. Bank as soon as practicable (but no later than the close of business as of February 26, 2021), (2) it will not revoke such instructions, (3) it has sufficient funds in the relevant account to cover the amount of such filing fee and (4) it will confirm receipt of such instructions by its bank during regular business hours no later than February 26, 2021.

 

 

 

 

PART II INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 16.

Exhibits and Financial Statement Schedules.

 

(a) Exhibits. All exhibits filed with or incorporated by reference in the Prior Registration Statement on Form S-1 (SEC File No. 333-252863) are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed herewith, as part of this Registration Statement:

 

Exhibit   Description
5.1   Opinion of Walkers
5.2   Opinion of Shearman & Sterling LLP
23.1   Consent of Marcum LLP
23.2   Consent of Walkers (included in Exhibit 5.1)
23.3   Consent of Shearman & Sterling LLP (included in Exhibit 5.2)
24   Power of Attorney (included in signature page to the Registrant’s Prior Registration Statement (File No. 333-252863) filed on February 9, 2021

  

II-1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Philadelphia, State of Pennsylvania, on the 25th day of February, 2021.

 

  IBERE PHARMACEUTICALS
     
  By:   
     
  /s/ Osagie Imasogie
  Name:  Osagie Imasogie
  Title: Chief Executive Officer

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

 

Name   Position   Date
         
/s/ Osagie Imasogie   Chairman, Chief Executive Officer and Director   February 25, 2021
Osagie Imasogie   (principal executive officer)    
    Chairman, Chief Executive Officer and Director    
         
/s/ Lisa Gray   Chief Financial Officer, Executive Vice President and Director   February 25, 2021
Lisa Gray   (principal financial and accounting officer)    
    Chief Financial Officer, Executive Vice President and Director    

 

II-2